To clarify the role of EPA-FFA on NOTCH1 pathway and in order to evaluate the ability of EPA-FFA to prevent the EMT phenotype led by CM, we assayed MMP9 activity by gelatin zymography on CRC cells treated with CM alone or following a 72 h EPA-FFA pre-treatment. This evidence concerns the gene NOTCH1 and colorectal carcinoma.